Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19016775 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL19016031 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL20587389 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL18988786 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL19016035 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL19016847 | 0.92 | RAF1 (0.64) | RAF1BRAF | |
| SCHEMBL23644586 | 0.90 | RAF1 (0.61) | RAF1BRAF | |
| SCHEMBL19016482 | 0.90 | RAF1 (0.61) | RAF1BRAF | |
| SCHEMBL18989116 | 0.90 | BRAF (0.61) | RAF1BRAF | |
| SCHEMBL23644589 | 0.88 | RAF1 (0.61) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-13 | — | — | US | disclosed |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-13 | — | — | US | disclosed |
| US-20180362542-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2017103824-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362542-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | BRAF, RAF1, MAP3K1 | RAF1 2/4885BRAF 1/4885 |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | BRAF, RAF1, MAP3K1 | RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.